Injective ETF: 21Shares Files New Fund for DeFi Investors

21Shares has filed for a new exchange-traded fund (ETF) focused on Injective (INJ), reports Coin Bureau. This is an important move that links decentralized finance (DeFi) with traditional finance. With this filing, Injective becomes one of the few digital assets with multiple ETFs in progress. The news shows growing interest from institutional investors.

🚨21SHARES FILES FOR INJECTIVE ETF!$INJ now joins the shortlist of assets with multiple ETF products in progress. pic.twitter.com/xoJVvYRHeF

— Coin Bureau (@coinbureau) October 21, 2025

What Is Injective?

Injective is a high-performance blockchain built for decentralized finance. It can handle more than 25,000 transactions per second. Its native token, INJ, helps keep the network safe through delegated proof-of-stake.

The network solves common blockchain problems like slow transaction finality and fragmented liquidity. It combines exchange features with fast finality powered by Comet BFT. This lets developers build DeFi applications efficiently.

Growing Institutional Interest

21Shares’ ETF filing shows the rising interest from institutional investors. Many traditional finance firms are now exploring ways to offer crypto assets to clients.

By creating ETFs, they provide a regulated and simple way for investors to access digital assets. This is especially important for investors who want exposure to crypto without holding the tokens directly.

The filing also shows that DeFi is gaining credibility. More financial firms are recognizing the value of innovative blockchains like Injective.

Benefits for Investors

For investors, an Injective ETF makes it easier to participate in the INJ market. ETFs are familiar to many investors. They offer exposure without requiring wallets or private keys.

The proposed ETF would hold INJ tokens in cold storage. This makes sure the tokens are safe while allowing investors to track the market price. Such structures are similar to spot ETFs for Bitcoin and Ethereum.

Investors can gain exposure to a fast-growing blockchain while staying within traditional financial frameworks.

Next Steps for Injective ETF

The ETF filing is now under review by regulators. Approval could open the door for similar ETFs focused on other DeFi tokens.

If approved, this move would bridge the gap between traditional finance and decentralized technologies. It could also encourage more institutional participation in the DeFi sector.

For now, the crypto community is watching closely. Traders and investors are curious about how this ETF will shape the market.

DeFi Gains Mainstream Attention

This filing shows a growing cryptocurrency market. Traditional finance tools are being applied to digital assets. As a result, more investors may feel confident entering the DeFi space.

Moreover, Injective’s inclusion in multiple ETFs highlights its growing importance in the crypto ecosystem. Companies like 21Shares are helping to make DeFi more accessible and safe.

Overall, the new ETF is a step toward mainstream adoption. It shows that digital assets are increasingly being taken seriously by regulators, investors and financial institutions.